Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Roche’s surge in sales for its long-acting macular degeneration drug Vabysmo showed that patients in the market are open to switching to another treatment.

While that was bad news for Regeneron and its formerly dominant Eylea, the company has countered Roche with its own longer-acting formulation of the anti-VEGF drug.